CheckMate 9LA研究：拓展非小细胞肺癌患者的治疗选择 - Suppr

Suppr

超能文献

CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer.

作者信息

Passaro Antonio, Attili Ilaria, de Marinis Filippo

机构信息

Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan 20141, Italy.

出版信息

Lancet Oncol. 2021 Feb;22(2):157-159. doi: 10.1016/S1470-2045(20)30701-4. Epub 2021 Jan 18.

DOI:10.1016/S1470-2045(20)30701-4

PMID:33476592

Abstract

摘要

相似文献

CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer.CheckMate 9LA研究：拓展非小细胞肺癌患者的治疗选择

Lancet Oncol. 2021 Feb;22(2):157-159. doi: 10.1016/S1470-2045(20)30701-4. Epub 2021 Jan 18.

Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.纳武利尤单抗±伊匹单抗（CheckMate 032）对比其他治疗方案用于复发性小细胞肺癌的间接比较。

J Comp Eff Res. 2019 Jul;8(10):733-751. doi: 10.2217/cer-2018-0130. Epub 2019 Jun 25.

Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA".对标题为“一线纳武利尤单抗联合伊匹木单抗与化疗治疗转移性非小细胞肺癌：CheckMate 9LA的更新结果”的致编辑信的回复

J Thorac Oncol. 2023 Sep;18(9):e102-e103. doi: 10.1016/j.jtho.2023.05.022.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.纳武利尤单抗联合伊匹木单抗对比化疗作为高肿瘤突变负荷的晚期非小细胞肺癌的一线治疗：来自随机、开放标签、III 期 CheckMate 227 试验的患者报告结局结果。

Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11.

Nivolumab improves survival for patients with advanced lung cancer.纳武单抗可提高晚期肺癌患者的生存率。

Cancer. 2017 Sep 1;123(17):3211. doi: 10.1002/cncr.30930.

First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA.一线纳武利尤单抗联合伊匹木单抗与化疗治疗转移性非小细胞肺癌：CheckMate 9LA研究的更新结果

J Thorac Oncol. 2023 Sep;18(9):e101-e102. doi: 10.1016/j.jtho.2022.11.024.

Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.纳武单抗（欧狄沃°）与转移性或不可切除的肺癌

Prescrire Int. 2017 Apr;26(181):93-94.

Nivolumab in non-small-cell lung cancer with EGFR mutation.纳武利尤单抗用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌

Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745.

Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.CheckMate 057 研究中纳武利尤单抗或多西他赛治疗晚期非鳞状非小细胞肺癌患者的健康相关生活质量和症状评估。

Eur J Cancer. 2018 Oct;102:23-30. doi: 10.1016/j.ejca.2018.05.005. Epub 2018 Aug 10.

[Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].[纳武单抗治疗非小细胞肺癌（NSCLC）引起的暴发性心肌炎：一例报告]

Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1047-1048. doi: 10.3760/cma.j.cn112152-20200116-00042.

引用本文的文献

Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy.SP263评估的程序性死亡受体配体1（PD-L1）表达对接受放化疗的Ⅲ期非小细胞肺癌（NSCLC）患者预后影响的评估

Biomedicines. 2024 Mar 19;12(3):688. doi: 10.3390/biomedicines12030688.

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.肺癌抗 PD-1/PD-L1 免疫治疗疗效预测生物标志物的研究进展。

Front Immunol. 2023 Jul 3;14:1227797. doi: 10.3389/fimmu.2023.1227797. eCollection 2023.

TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.TRIM17介导的RBM38泛素化和降解促进非小细胞肺癌的顺铂耐药。

Cell Oncol (Dordr). 2023 Oct;46(5):1493-1507. doi: 10.1007/s13402-023-00825-6. Epub 2023 May 23.

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.转移性非小细胞肺癌的免疫治疗：治疗进展和生物标志物。

Curr Oncol. 2023 Feb 16;30(2):2366-2387. doi: 10.3390/curroncol30020181.

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.帕博利珠单抗联合化疗与单纯化疗治疗PD-L1＜50%的转移性非鳞状非小细胞肺癌的真实世界数据（RWD）对疗效和进展后结局的分析比较

Front Oncol. 2022 Aug 10;12:980765. doi: 10.3389/fonc.2022.980765. eCollection 2022.

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.通过联合治疗和 PD-L1 调控提高 PD-1/PD-L1 阻断的抗癌疗效。

J Hematol Oncol. 2022 Mar 12;15(1):24. doi: 10.1186/s13045-022-01242-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验